(Q37873715)

24 August 2017

1 reference

title

Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment (English)

1 reference

metabolic dysfunction–associated steatotic liver disease

24 August 2017

0 references

0 references

1 reference

1 reference

Briohny W Smith

1

1 reference

PubMed ID

21556019

24 August 2017

Leon A Adams

series ordinal

2

1 reference

24 August 2017

10 May 2011

1 reference

Nature Reviews Endocrinology

24 August 2017

1 reference

24 August 2017

7

1 reference

24 August 2017

8

1 reference

24 August 2017

456-465

1 reference

https://scigraph.springernature.com/pub.10.1038/nrendo.2011.72

24 August 2017

0 references

cites work

Nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Long-term follow-up of patients with nonalcoholic fatty liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Global estimates of the prevalence of diabetes for 2010 and 2030

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Prevalence of and risk factors for fatty liver in a general population of Shanghai, China

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Prevalence of fatty liver in children and adolescents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Idiopathic steatohepatitis in childhood: a multicenter retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Fatty liver--an additional and treatable feature of the insulin resistance syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Nonalcoholic Steatohepatitis in Children

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Prevalence and Predictors of Asymptomatic Liver Disease in Patients Undergoing Gastric Bypass Surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Hepatic histology in obese patients undergoing bariatric surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Non-alcoholic steatohepatitis in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Screening for liver fibrosis by using a noninvasive biomarker in patients with diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Newly diagnosed diabetes mellitus as a risk factor for serious liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Influence of hepatic steatosis (fatty liver) on severity and composition of dyslipidemia in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Nonalcoholic fatty liver disease in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Liver fibrosis in overweight patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Long term prognosis of fatty liver: risk of chronic liver disease and death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Non-alcoholic hepatic steatosis and its relation to increased plasma biomarkers of inflammation and endothelial dysfunction in non-diabetic men. Role of visceral adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: "double diabetes" in the Diabetes Control and Complications Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Abnormal liver function tests in patients with Type 1 diabetes mellitus: prevalence, clinical correlations and underlying pathologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Glycogenic hepatopathy: an underrecognized hepatic complication of diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Ethnic differences in hepatic steatosis: an insulin resistance paradox?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Non-alcoholic fatty liver disease and its association with obesity, insulin resistance and increased serum levels of C-reactive protein in Hispanics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Influence of ethnicity on histological differences in non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Genetics of common obesity and nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Heritability of nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Unravelling the pathogenesis of fatty liver disease: patatin-like phospholipase domain-containing 3 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Genetic and environmental susceptibility to non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Apolipoprotein synthesis in nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Dissociation of Hepatic Steatosis and Insulin Resistance in Mice Overexpressing DGAT in the Liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: role of stearoyl-CoA desaturase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Metabolic stress signaling mediated by mixed-lineage kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Inflammation and metabolic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

A stress signaling pathway in adipose tissue regulates hepatic insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

JNK1 in hematopoietically derived cells contributes to diet-induced inflammation and insulin resistance without affecting obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

A central role for JNK in obesity and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Hepatocyte CYP2E1 overexpression and steatohepatitis lead to impaired hepatic insulin signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Visceral fat: a key mediator of steatohepatitis in metabolic liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Subcutaneous and visceral adipose tissue: structural and functional differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Obesity is associated with macrophage accumulation in adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Inflammation and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Beyond insulin resistance in NASH: TNF-alpha or adiponectin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Leptin is essential for the hepatic fibrogenic response to chronic liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

The metabolic abnormalities associated with non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

High glucose stimulates hepatic stellate cells to proliferate and to produce collagen through free radical production and activation of mitogen-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

The utility of radiological imaging in nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Diagnosis and therapy of nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Abnormal glucose tolerance in young male patients with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Noninvasive assessment of hepatic steatosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Role of radiologic modalities in the management of non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

In vivo 3T spectroscopic quantification of liver fat content in nonalcoholic fatty liver disease: Correlation with biochemical method and morphometry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

The natural history of nonalcoholic fatty liver disease: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Fitness versus fatness: moving beyond weight loss in nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Effect of calorie restriction with or without exercise on insulin sensitivity, beta-cell function, fat cell size, and ectopic lipid in overweight subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Effects of diet and exercise on muscle and liver intracellular lipid contents and insulin sensitivity in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Cardiovascular outcomes in trials of oral diabetes medications: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Treatment of non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

L-carnitine supplementation to diet: a new tool in treatment of nonalcoholic steatohepatitis--a randomized and controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Nonalcoholic Fatty Liver Disease in Severely Obese Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Nonalcoholic steatohepatitis: An expanded clinical entity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Increased prevalence of cardiovascular disease in Type 2 diabetic patients with non-alcoholic fatty liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Non-alcoholic fatty liver disease is associated with carotid artery wall thickness in diet-controlled type 2 diabetic patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

The JNK signal transduction pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Inflammation, stress, and diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Leptin, liver, and obese mice--fibrosis in the fat lane

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

The role of ultrasound in the diagnosis of hepatic steatosis in morbidly obese patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Introduction of fast MR imaging in the assessment of hepatic steatosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

A position statement on NAFLD/NASH based on the EASL 2009 special conference

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Independent effects of physical activity in patients with nonalcoholic fatty liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Bariatric surgery for non-alcoholic steatohepatitis in obese patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

An editorial update: Annus horribilis for vitamin E

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.72

Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions

31 March 2020

1 reference

12 December 2020

Nonalcoholic fatty liver disease

1 reference

12 December 2020

Correlates and heritability of nonalcoholic fatty liver disease in a minority cohort

1 reference

12 December 2020

The prevalence and etiology of elevated aminotransferase levels in the United States

1 reference

12 December 2020

Liver fat, serum triglycerides and visceral adipose tissue in insulin-sensitive and insulin-resistant black men with NIDDM

1 reference

12 December 2020

Prevalence of liver abnormalities in the general population of Okinawa, Japan

1 reference

12 December 2020

Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease

1 reference

12 December 2020

Diabetic hepatosclerosis: diabetic microangiopathy of the liver

1 reference

12 December 2020

Non-alcoholic steatohepatitis in children and adolescents

1 reference

12 December 2020

Molecular mediators of hepatic steatosis and liver injury

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRENDO.2011.72

1 reference

24 August 2017

1 reference

PubMed ID

21556019